Sort
64,565 grants matching “drug discovery”
Sigma 1 receptor as therapeutic target for Alzheimers disease treatment
$700,007James S. Malter · Ut Southwestern Medical Center · R56 · FY2023 · AG
Photoactivation of Stable Bonds for Chemical Conversions
$700,000Daniel G Nocera · Harvard University · · FY2023 · MPS
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
$700,000David Eric Gerber · Ut Southwestern Medical Center · U10 · FY2017 · CA
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** FUNGAL PATHOGENS CAUSE DEVASTATING DISEASE IN CROP PLANTS WORLDWIDE, THREATENING GLOBAL FOOD SECURITY. FUNGAL DISEASES CAN ALSO TARGET NATIVE PLANT AND ANIMAL SPECIES, LEADING TO IRREVERSIBLE ECOLOGICAL DAMAGE. IN HUMANS, FUNGAL DISEASES ARE OFTEN OVERLOOKED, BUT KILL 1.5 MILLION PEOPLE A YEAR. DESPITE THE DANGER FUNGAL PATHOGENS POSE, CURRENT FUNGAL DISEASE MANAGEMENT STRATEGIES ARE LIMITED TO MAINLY CHEMICAL CONTROL. FUNGICIDE APPLICATION OFTEN LEAVES HARMFUL RESIDUES IN THE ENVIRONMENT, AND RESISTANT FUNGI HAVE BEEN REPORTED FOR ALMOST ALL MAJOR CLASS OF FUNGICIDES AND ANTIFUNGAL DRUGS USED IN AGRICULTURAL AND CLINICAL SETTINGS. IN ORDER TO SAFEGUARD GLOBAL FOOD SECURITY, HUMAN HEALTH, AND ECOLOGICAL BIODIVERSITY, IT IS IMPERATIVE THAT NEW TECHNOLOGIES FOR COMBATTING FUNGAL DISEASE ARE DEVELOPED. THE PI'S LAB DISCOVERED THAT SMALL RNAS (SRNAS) CAN BE TRANSPORTED BETWEEN PLANT HOSTS AND THEIR FUNGAL PATHOGENS AND INDUCE TARGET GENE SILENCING IN THE COUNTERPART THROUGH A PHENOMENON CALLED CROSS-KINGDOM RNA INTERFERENCE (RNAI). DURING THE LAST FUNDING PERIOD, THE PI'S LAB FURTHER DEMONSTRATED THAT PLANTS SEND SRNAS INTO FUNGAL CELLS USING EXTRACELLULAR VESICLES, SECRETED MEMBRANE ENCAPSULATED STRUCTURES THAT ARE IMPORTANT FOR INTERCELLULAR COMMUNICATION. FURTHERMORE, THE PI'S LAB DISCOVERED THAT FUNGAL CELLS CAN TAKE UP RNAS FROM THE ENVIRONMENT. THIS DISCOVERY HAS PROMPTED THE DEVELOPMENT OF A NEW FUNGAL DISEASE MANAGEMENT STRATEGY, SPRAY-INDUCED GENE SILENCING (SIGS), WHERE FUNGAL GENE-TARGETING RNAS ARE SPRAYED ONTO PLANTS AND TAKEN UP BY FUNGAL CELLS AND SILENCE FUNGAL VIRULENCE-RELATED GENES TO CONFER DISEASE PROTECTION. SIGS HAS BEEN SUCCESSFULLY UTILIZED TO INHIBIT MULTIPLE FUNGAL DISEASES ON BOTH PRE- AND POST-HARVESTING PLANTS. UNLIKE TRADITIONAL FUNGICIDES, RNAS ARE SAFE TO INGEST, AND DO NOT LEAVE TOXIC RESIDUES IN THE SOIL. THIS PROJECT AIMS TO IDENTIFY KEY FUNGAL VIRULENCE-RELATED GENES AND DESIGN SPECIFIC AND SAFE SIGS RNAS TO EFFECTIVELY INHIBIT FUNGAL DISEASES ON PRE- AND POST-HARVESTING PLANTS. PLANT AGGRESSIVE FUNGAL PATHOGENS BOTRYTISSCLEROTINIA SCLEROTIORUM, ASPERGILLUS NIGER AND VERTICILLIUM DAHLIAE, THE ECONOMICALLY IMPORTANT PATHOGENS THAT HAVE BROAD PLANT HOST RANGE AND CAUSE SERIOUS CROP LOSSES WORLDWIDE, WERE CHOSEN FOR THIS STUDY. THIS PROJECT WILL ADDRESS THE MAJOR CHALLENGES OF SIGS APPROACHES TO ENHANCE THE SIGS RNA STABILITY AND FUNGAL UPTAKE EFFICIENCY BY DEVELOPING ORGANIC AND INORGANIC RNA DELIVERY VEHICLES, AND TO DEVELOP COST-EFFECTIVE METHODS FOR SIGS RNA PRODUCTION. ALTHOUGH OUR PRELIMINARY DATA SUGGEST THAT DOCKING SIGS RNAS TO ORGANIC OR INORGANIC CARRIER MOLECULES CAN GREATLY ENHANCE THE SPAN OF TIME THEY CONFER PROTECTION, BUT THEY ARE STILL UNSTABLE IN THE SOIL. TO DEVELOP EFFECTIVE SIGS TO CONTROL SOIL-BORNE FUNGAL PATHOGEN. WE PROPOSE TO DEPLOY BENEFICIAL BACTERIUM AND FUNGUS, B. SUBTILIS AND TRICHODERMA VIRENS, RESPECTIVELY, FOR CONTINUOUS PRODUCTION AND DELIVERY OF SIGS RNAS TO THE RHIZOSPHERE. FURTHERMORE, THIS APPROACH CAN POTENTIALLY BE ADAPTED TO MANIPULATE SOIL MICROBIOME COMPOSITION USING RNA-PRODUCING BENEFICIAL MICROBES TO PROMOTE CROP PRODUCTION.
$700,000Regents Of The University Of California At Riverside · · FY2021 · National Institute of Food and Agriculture
CWRU OBRIEN RENAL RESEARCH CENTER
$700,000Case Western Reserve University · P50 · FY2001 · DK
ComPASS Collective for Community Engagement (C3E)
$700,000Wesley H Self · Vanderbilt University Medical Center · UL1 · FY2023 · TR
Prevalence and Functional Significance of Regulated Alternative Splicing in Plant Pathogenic Fungi
$700,000Ioannis Stergiopoulos · University Of California-Davis · · FY2016 · BIO
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
$700,000Joan H Schiller · Ut Southwestern Medical Center · U10 · FY2015 · CA
DCTD Functional Genomics
$700,000Larry Arthur · Science Applications International Corp · N01 · FY2009 · CA
CWRU OBRIEN RENAL RESEARCH CENTER
$700,000Case Western Reserve University · P50 · FY2000 · DK
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
$700,000G. Yancey Gillespie · University Of Alabama At Birmingham · P20 · FY2013 · CA
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
$700,000G. Yancey Gillespie · University Of Alabama At Birmingham · P20 · FY2012 · CA
MRI Consortium: Development of Sample Delivery Instrument for Femtosecond Diffraction Studies
$700,000Soichi Wakatsuki · Stanford University · · FY2016 · BIO
Rational Design of Atomically Precise Catalysts for Parahydrogen Enhanced Nuclear Magnetic Resonance Imaging and Spectroscopy
$699,967Helena E Hagelin-Weaver · University Of Florida · · FY2019 · ENG
Lysosomal Diseases
$699,963Rosa Puertollano · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL
Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimer's
$699,915Susan M Catalano · Cognition Therapeutics, Inc. · U01 · FY2014 · AG
A High-Throughput Platform for COVID-19 Serodiagnosis, Vaccine Evaluation, and Drug Discovery
$699,894Ricardo Rajsbaum · University Of Texas Med Br Galveston · R01 · FY2020 · AI
MRI: Acquisition of a Field Emission Cryo-Scanning Electron Microscope for Nanocharacterization and Patterning of Soft Materials
$699,848Matthew R Libera · Stevens Institute Of Technology · · FY2009 · MPS
Biochemical, Biophysical, and Structural Mechanisms of HIV-1 Budding and Release
$699,815James H Hurley · University Of California Berkeley · R37 · FY2024 · AI
Plasmodium and Anopheles midgut interactive proteins influence malaria transmission
$699,814Jun Li · Florida International University · R01 · FY2025 · AI
Tools for Accelerating R&D for Historically Understudied Protein Kinases
$699,809Reena Zutshi · Luceome Biotechnologies, Llc · R44 · FY2018 · TR
Preclinical optimization of a parasiticidal drug for cryptosporidiosis
$699,764Christopher D Huston · University Of Vermont & St Agric College · R01 · FY2023 · AI
Accelerating Functional Maturation of Human Neurons for High-Throughput Screening
$699,736Zhong-Wei Du · Brainxell, Inc. · R44 · FY2019 · DA
In vivo HTS assay for novel modulators of Apolipoprotein B
$699,728Steven A Farber · Carnegie Institution Of Washington, D.C. · R01 · FY2021 · DK
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension
$699,718Evan L Brittain · Vanderbilt University Medical Center · R01 · FY2025 · HL